Published
April 6, 2026
If you took generic Aurobindo irbesartan for blood pressure since 2016, this $2 million settlement covered what you overpaid for a drug allegedly tainted with the probable carcinogen NDEA — the June 2, 2026 claim deadline has now passed.
What Is This Settlement About?
Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., and Aurolife Pharma LLC have agreed to a $2,000,000 class action settlement to resolve economic loss claims that the company manufactured and sold irbesartan blood pressure drugs allegedly contaminated with NDEA — a probable human carcinogen. The settlement is part of the massive multidistrict litigation in the U.S. District Court for the District of New Jersey covering contamination across the entire family of generic sartan blood pressure medications. It is one of three related settlements, alongside the $11.37 million Hetero Valsartan settlement and the $1.899 million Vivimed Losartan settlement.Irbesartan is a generic prescription drug used to treat high blood pressure (hypertension) and to protect the kidneys in people with type 2 diabetes. It belongs to the angiotensin II receptor blocker (ARB) family of drugs, often called "sartans," which also includes valsartan and losartan. Aurobindo manufactures irbesartan finished drug formulations using its own active pharmaceutical ingredient (API) made through what the company calls its "IC Route of Synthesis."
The lawsuit alleges that this manufacturing process produced API contaminated with NDEA (N-nitrosodiethylamine), a nitrosamine impurity classified by health regulators as a probable human carcinogen. The contamination triggered FDA recalls of multiple sartan medications starting in 2018 and led to consolidated nationwide litigation against the manufacturers. Aurobindo denies all allegations of wrongdoing and denies that the NDEA levels in its irbesartan were harmful or carcinogenic.
This settlement resolves only the economic loss claims — meaning what consumers and insurers overpaid for a drug that was allegedly defective. It does not cover personal injury or medical monitoring claims, which are being litigated separately in the same MDL. It also does not affect any claims related to losartan or valsartan.
Status
Claims Open
final approval hearing scheduled June 30, 2026
Claim Deadline
June 2, 2026
Settlement Fund
$2,000,000
economic loss only · pro rata refund · class period Jan 1, 2016 – present
Proof Required
No
documentation encouraged but not strictly required · Aurobindo IC ROS irbesartan
Who Qualifies?
You are a member of the consumer settlement class if you are an individual in the United States who, from January 1, 2016 to the present, paid any amount of money for retail purchases of irbesartan finished drug formulations manufactured using Aurobindo irbesartan API made through Aurobindo's IC Route of Synthesis ("IC ROS Irbesartan").That covers a long class period — nearly a decade. Aurobindo is one of the largest generic drug manufacturers in the world and supplies irbesartan to many U.S. pharmacies. If you have taken generic irbesartan to manage high blood pressure or diabetic kidney disease at any point since 2016, there is a real chance that some or all of your prescriptions came from Aurobindo.
How to confirm Aurobindo was your manufacturer: check the label on any old irbesartan pill bottles you still have. The manufacturer is printed on the label. If you no longer have the bottle, your pharmacy can print your full prescription history showing the manufacturer of each fill. Most major pharmacies (CVS, Walgreens, Rite Aid, Walmart, Kroger, Costco, independent pharmacies) will print this for free upon request.
Excluded from the class are Aurobindo itself and its officers, pharmacy benefit managers, most federal and state government entities, personal injury plaintiffs in the MDL, and anyone who timely opts out of the settlement.
How Much Can I Get?
The total settlement fund is $2,000,000. Attorneys' fees (up to one-third, or approximately $666,667), litigation costs, settlement administration expenses, and service awards to the named plaintiffs will be deducted before distribution. The net fund will then be allocated between consumers and third-party payors (like health insurers and welfare funds) according to a method approved by the court.Individual payouts depend on how much you paid for Aurobindo irbesartan during the class period and how many valid claims are filed. Payments will be made pro rata, meaning the more you spent, the larger your share. Because irbesartan is a long-term prescription for blood pressure management, people who took Aurobindo irbesartan for months or years could see meaningful payouts.
Do I Need Proof?
The notice says documentation should be submitted to support your claim if possible, but does not strictly require proof of purchase upfront. Here is the process:• You file your claim form and describe your Aurobindo irbesartan purchases.
• The settlement administrator reviews your claim with attention to fraud and mistaken claims.
• If your documentation is insufficient to approve the claim, the administrator may contact you for proof of purchase from your pharmacy.
• You then provide the requested documentation.
To prevent delays, it is best to include whatever proof you have with your initial claim. Acceptable documentation includes pharmacy receipts, prescription bottle labels showing Aurobindo as the manufacturer, insurance explanation of benefits statements, or a pharmacy-printed prescription history. Your pharmacy can print your prescription history for free.
How Do I File a Claim?
Submit your claim online at SartanMedicationSettlement.com, or download a paper claim form from that website and mail the completed form to the Settlement Administrator at the address listed in the official notice. Your claim must be submitted online or postmarked by June 2, 2026.This settlement is part of a broader group of three related settlements involving contaminated sartan blood pressure drugs. If you also purchased Hetero valsartan (sold May – July 2018) or Vivimed losartan (specific NDCs), you can file claims for those settlements through the same website. See our combined sartan blood pressure drug settlement page for details on all three, or our news alert, $15.26 million blood pressure drug settlement deadline (June 2, 2026), if you are filing on the last day.
When Will Payments Be Sent?
The final approval hearing is scheduled for June 30, 2026 at 10:00 AM at Courtroom 3D of the U.S. District Court for the District of New Jersey, before Judge Renee M. Bumb. If the court grants final approval and no appeals are filed, the settlement administrator will begin distributing payments after the effective date defined in the court's final approval order. The exact timing depends on how long claims processing takes after the court approves the settlement.Case Information
This settlement is part of In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK (MDL No. 2875), in the U.S. District Court for the District of New Jersey, before Judge Renee M. Bumb. The defendants are Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., and Aurolife Pharma LLC. The allegation is that Aurobindo irbesartan manufactured using the IC Route of Synthesis was contaminated with NDEA, a probable human carcinogen. The class period runs from January 1, 2016 to the present. Class counsel are Slack Davis Sanger LLP, Honik Law, and Kanner & Whiteley LLC, and the class representatives are Jacqueline Harris (consumer) and MSP Recovery Claims Series LLC (third-party payor). The claim, opt-out, and objection deadlines are all June 2, 2026.Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
Claim Form Website: SartanMedicationSettlement.com
Submit Claim
Official Settlement Notice (PDF)
Sources
• Official Settlement Website — SartanMedicationSettlement.com• Court-authorized Aurobindo Settlement Notice, In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875-RBK-SAK (D.N.J.)
• OpenClassActions — Combined Sartan Blood Pressure Drug Settlement Overview
• OpenClassActions — Hetero Valsartan Settlement In-Depth Guide ($11.37M)
• OpenClassActions — Vivimed Losartan Settlement ($1.899M)
For more class actions keep scrolling below.
Settlement Amount
$2,000,000
Case Title
In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation
Case Number
1:19-md-02875-RBK-SAK (MDL No. 2875)
Court
U.S. District Court, District of New Jersey
Final Approval Hearing
June 30, 2026 at 10:00 AM
Courtroom 3D, D.N.J. · Judge Renee M. Bumb
Defendants
Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC
Official Website
Sartan Medication Settlement.com
